近期中外幽门螺杆菌根除治疗处理共识报告对比解读
Reconciliation of recent western and eastern consensus on treatment of Helicobacter pylori eradication
彭若琳 1张振玉1
作者信息
- 1. 南京医科大学附属南京医院(南京市第一医院)消化内科,江苏 南京 210006
- 折叠
摘要
幽门螺杆菌(Helicobacter pylori,H.pylori)是主要的胃癌致病因子,也是消化系统内外多种疾病的重要致病因素,为了规范H.pylori的治疗以降低胃癌发病率,国内外相关共识也在不断更新.2022 年,中国和欧洲均发布了最新的 H.pylori处理共识报告,即《2022 中国幽门螺杆菌感染治疗指南》和《幽门螺杆菌感染的管理:马斯特里赫特Ⅵ/佛罗伦萨共识报告》,本文将从 H.pylori根除治疗的抗生素管理、根除方案、根除流程、根除疗程、加强抑酸、其他辅助用药六个方面回顾上述指南并进行对比解读,为临床规范化根除 H.pylori治疗提供参考依据.
Abstract
Helicobacter pylori(H.pylori)is a major pathogenic factor for gastric cancer and an important pathogenic factor for gastrointestinal disease and affects other human systems.In order to regulate the treatment of H.pylori and re-duce the incidence of gastric cancer,western and eastern consensus is constantly updated.In 2022,both China and Eu-rope released the latest consensus reports on H.pylori management,namely ″2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment″ and ″Management of Helicobacter pylori infection:the Maastricht Ⅵ/Florence consensus report″.In this paper,the above guidelines would be reviewed and compared from six aspects:antibiotic management,eradication program,eradication process,eradication course,enhancement of acid inhibition and other adjuvant drugs,so as to provide reference for standardized clinical eradication of H.pylori therapy.
关键词
幽门螺杆菌/共识/治疗/抗生素Key words
Helicobacter pylori/Consensus/Treatment/Antibiotics引用本文复制引用
出版年
2024
NETL
NSTL
万方数据